Cubist Systematic Strategies LLC Grows Holdings in Humana Inc (HUM)

Cubist Systematic Strategies LLC boosted its position in shares of Humana Inc (NYSE:HUM) by 1,327.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,738 shares of the insurance provider’s stock after purchasing an additional 4,406 shares during the period. Cubist Systematic Strategies LLC’s holdings in Humana were worth $1,154,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in HUM. Koch Industries Inc. bought a new position in shares of Humana in the 2nd quarter valued at about $404,000. Adviser Investments LLC bought a new position in shares of Humana in the 3rd quarter valued at about $635,000. Teachers Advisors LLC grew its holdings in shares of Humana by 31.6% in the 2nd quarter. Teachers Advisors LLC now owns 630,835 shares of the insurance provider’s stock valued at $151,792,000 after acquiring an additional 151,603 shares in the last quarter. Prisma Capital Partners LP bought a new position in shares of Humana in the 2nd quarter valued at about $7,122,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Humana by 10.0% in the 3rd quarter. Wells Fargo & Company MN now owns 1,653,318 shares of the insurance provider’s stock valued at $402,799,000 after acquiring an additional 150,173 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Humana Inc (HUM) opened at $246.38 on Tuesday. Humana Inc has a 1-year low of $186.25 and a 1-year high of $264.56. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $36,207.89, a PE ratio of 21.63, a P/E/G ratio of 1.74 and a beta of 0.88.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.12. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. Humana’s quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter last year, the company posted $3.18 earnings per share. analysts forecast that Humana Inc will post 11.63 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 annualized dividend and a yield of 0.65%. Humana’s dividend payout ratio (DPR) is presently 12.59%.

Humana announced that its Board of Directors has initiated a stock buyback program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the insurance provider to repurchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Several equities analysts have recently weighed in on HUM shares. BMO Capital Markets raised their price objective on Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, November 10th. ValuEngine upgraded Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Royal Bank of Canada restated a “sector perform” rating and issued a $242.00 price objective (down previously from $245.00) on shares of Humana in a report on Thursday, November 9th. Credit Suisse Group decreased their price objective on Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Finally, Zacks Investment Research cut Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 17th. Twelve equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $256.30.

COPYRIGHT VIOLATION WARNING: This article was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://sportsperspectives.com/2017/12/19/cubist-systematic-strategies-llc-grows-holdings-in-humana-inc-hum.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply